With over 20 years of experience as a life sciences company builder and operator, Chad Holland, CEO and president of ALZpath, is a seasoned executive known for his proficiency in managing various product and company stages. He has a proven track record in entrepreneurial leadership, product launches, alliance management, business development, and sales & marketing. Prior to his current role, Chad was the Chief Commercial Officer at Valo Health.
Throughout his career, Chad has contributed to the success of diverse companies, including Danaher Corporation, Voyager Therapeutics, Enobia Pharma (acquired by Alexion), Synhale Therapeutics, and Mylan, as well as Stryker, Medtronic, and SC Johnson. His educational background includes an undergraduate degree in Chemical Engineering from the University of Wisconsin, an MBA from the Kellogg School of Management at Northwestern University, and dual Master’s degrees from the Harvard-MIT Biomedical Enterprise Program.
Early diagnosis through blood tests buys invaluable time – for patients and their families to plan, seek support, make informed decisions about their difficult care journey and, perhaps most importantly, be together.